CAD 3.44
(2.99%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 919.08 Thousand CAD | -41.05% |
2022 | 1.55 Million CAD | -23.93% |
2021 | 2.04 Million CAD | -23.05% |
2020 | 2.66 Million CAD | -57.69% |
2019 | 6.29 Million CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | -100.0% |
2014 | 660.51 Thousand CAD | 28.0% |
2013 | 516.01 Thousand CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
2005 | - CAD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q3 | 412.68 Thousand CAD | 0.0% |
2024 Q2 | 588.3 Thousand CAD | 0.0% |
2024 Q1 | 737.32 Thousand CAD | 0.0% |
2023 Q1 | 1.38 Million CAD | -10.87% |
2023 Q2 | 1.23 Million CAD | -10.8% |
2023 Q3 | 1.06 Million CAD | -14.33% |
2023 FY | 919.08 Thousand CAD | -41.05% |
2023 Q4 | 919.08 Thousand CAD | -13.45% |
2022 FY | 1.55 Million CAD | -23.93% |
2022 Q2 | 1.79 Million CAD | -5.72% |
2022 Q3 | 1.67 Million CAD | -6.57% |
2022 Q1 | 1.9 Million CAD | -7.17% |
2022 Q4 | 1.55 Million CAD | -6.97% |
2021 Q4 | 2.04 Million CAD | -4.78% |
2021 Q1 | 2.45 Million CAD | -7.69% |
2021 Q2 | 2.3 Million CAD | -6.12% |
2021 Q3 | 2.15 Million CAD | -6.75% |
2021 FY | 2.04 Million CAD | -23.05% |
2020 Q3 | 2.87 Million CAD | -5.74% |
2020 Q2 | 3.05 Million CAD | 2.41% |
2020 FY | 2.66 Million CAD | -57.69% |
2020 Q1 | 2.97 Million CAD | -52.68% |
2020 Q4 | 2.66 Million CAD | -7.36% |
2019 Q3 | 6.14 Million CAD | -39.87% |
2019 FY | 6.29 Million CAD | 0.0% |
2019 Q2 | 10.21 Million CAD | 11.07% |
2019 Q1 | 9.19 Million CAD | 0.0% |
2019 Q4 | 6.29 Million CAD | 2.48% |
2018 Q3 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q1 | 703.59 Thousand CAD | 6.52% |
2015 Q4 | - CAD | -100.0% |
2015 FY | - CAD | -100.0% |
2015 Q2 | 748.03 Thousand CAD | 6.32% |
2015 Q3 | 780.14 Thousand CAD | 4.29% |
2014 FY | 660.51 Thousand CAD | 28.0% |
2014 Q1 | 549.32 Thousand CAD | 6.45% |
2014 Q3 | 621.48 Thousand CAD | 6.42% |
2014 Q4 | 660.51 Thousand CAD | 6.28% |
2014 Q2 | 584.01 Thousand CAD | 6.32% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | 516.01 Thousand CAD | 0.0% |
2013 FY | 516.01 Thousand CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q2 | - CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
2005 Q1 | - CAD | 0.0% |
2005 Q2 | - CAD | 0.0% |
2005 Q4 | - CAD | 0.0% |
2005 Q3 | - CAD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Arch Biopartners Inc. | 703.92 Thousand CAD | -30.566% |
Hemostemix Inc. | 4.32 Million CAD | 78.732% |
Universal Ibogaine Inc. | 1.73 Million CAD | 47.109% |
Kane Biotech Inc. | 1.3 Million CAD | 29.435% |
MedMira Inc. | 2.95 Million CAD | 68.921% |
Marvel Biosciences Corp. | 1 Million CAD | 8.092% |
NervGen Pharma Corp. | 105.6 Thousand CAD | -770.308% |
XORTX Therapeutics Inc. | - CAD | -Infinity% |